Antiangiogenic gene therapy
- 4 August 1998
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 95 (16), 9064-9066
- https://doi.org/10.1073/pnas.95.16.9064
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.Journal of Clinical Investigation, 1998
- Gene therapy strategies for tumor antiangiogenesisJNCI Journal of the National Cancer Institute, 1998
- Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth.Journal of Clinical Investigation, 1997
- Why are we doing so much cancer gene therapy? Disentangling the scientific basis from the origins of gene therapyGene Therapy, 1997
- Gene Therapy for CancerScientific American, 1997
- Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapyTrends in Pharmacological Sciences, 1995
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- VEGF-mediated tumour angiogenesis: a new target for cancer therapyCurrent Opinion in Biotechnology, 1995
- Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinomaCell, 1994
- Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agentsInternational Journal of Cancer, 1994